Respiratory syncytial virus after the SARS-CoV-2 pandemic — what next?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Energy Engineering and Power Technology,Fuel Technology
Link
https://www.nature.com/articles/s41577-022-00764-7.pdf
Reference10 articles.
1. Eden, J.-S. et al. Off-season RSV epidemics in Australia after easing of COVID-19 restrictions. Nat. Commun. 13, 2884 (2022).
2. Li, Y. et al. Understanding the potential drivers for respiratory syncytial virus rebound during the coronavirus disease 2019 pandemic. J. Infect. Dis. 225, 957–964 (2022).
3. Koutsakos, M., Wheatley, A. K., Laurie, K., Kent, S. J. & Rockman, S. Influenza lineage extinction during the COVID-19 pandemic? Nat. Rev. Microbiol. 19, 741–742 (2021).
4. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531–537 (1998).
5. Hammitt, L. L. et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants. N. Engl. J. Med. 386, 837–846 (2022).
Cited by 23 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Nirsevimab Immunization to Prevent Respiratory Syncytial Virus–Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age;Nursing for Women's Health;2024-02
2. Prevalence of respiratory viruses among hospitalized children with lower respiratory tract infections during the COVID-19 pandemic in Wuhan, China;International Journal of Infectious Diseases;2024-02
3. Metabolic reprograming and increased inflammation by cadmium exposure following early-life respiratory syncytial virus infection: the involvement of protein S-palmitoylation;Toxicological Sciences;2023-11-06
4. Effect of the COVID-19 pandemic on the pediatric infectious disease landscape;European Journal of Pediatrics;2023-09-20
5. Exploring the Immune Response against RSV and SARS-CoV-2 Infection in Children;Biology;2023-09-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3